Astellas Pharma vs. Lupin: Consent Judgment Upholds MYRBETRIQ® Patent Portfolio
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Astellas Pharma, Inc. v. Lupin Limited |
| Case Number | 1:24-cv-01068 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Sept 24, 2024 – Feb 19, 2026 1 year 5 months |
| Outcome | Plaintiff Win – Consent Judgment, Permanent Injunction |
| Patents at Issue | |
| Accused Products | Lupin’s ANDA No. 209485 (generic mirabegron extended-release tablets in 25 mg and 50 mg strengths) |
Case Overview
The Parties
⚖️ Plaintiff
Japan-headquartered global pharmaceutical company with a robust U.S. intellectual property portfolio. MYRBETRIQ® (mirabegron) is a commercially significant asset.
🛡️ Defendant
Major Indian multinational pharmaceutical company and one of the world’s largest generic drug manufacturers, known for ANDA filings with Paragraph IV certifications.
Patents at Issue
Four patents formed the core of this dispute, covering various aspects of MYRBETRIQ® (mirabegron) extended-release technology:
- • U.S. Patent No. 12,097,189 — covering formulation or method-of-use aspects.
- • U.S. Patent No. ‘780 — related to formulation, composition, and/or method-of-use claims.
- • U.S. Patent No. ‘451 — related to formulation, composition, and/or method-of-use claims.
- • U.S. Patent No. ‘409 — related to formulation, composition, and/or method-of-use claims.
Developing a generic drug?
Check if your product might infringe these or related pharmaceutical patents.
The Verdict & Legal Analysis
Outcome
The U.S. District Court for the District of Delaware entered a consent judgment against Lupin, following Lupin’s express admission that the ‘780, ‘451, ‘409, and ‘189 patents are valid and enforceable, and that at least one claim of each patent is infringed by Lupin’s ANDA products. No damages were awarded, as is typical in pre-launch Hatch-Waxman litigation.
The outcome is a permanent injunction prohibiting Lupin from making, using, selling, offering to sell, importing, or distributing the accused ANDA products in the United States through the expiration of all four asserted patents, including any patent term extensions, patent term adjustments, pediatric exclusivity, or other regulatory exclusivities.
Legal Significance & Strategic Takeaways
This case reinforces several important principles in pharmaceutical patent litigation:
- Multi-patent portfolio assertion remains a highly effective enforcement mechanism, creating overlapping layers of protection.
- The consent judgment structure allows patent holders to crystallize infringement and validity admissions while providing generic challengers with defined exit terms.
- Explicit references to patent term extension and regulatory exclusivity stacking in the injunction language illustrate how branded companies leverage all available IP and regulatory tools.
- The admissions are limited to Lupin ANDA No. 209485 and its specific products, preserving Lupin’s flexibility for future product development.
- The court retains jurisdiction to enforce compliance, including issuing preliminary injunctions against any breach, with parties waiving jurisdictional and venue defenses.
Drafting a pharmaceutical patent?
Learn from this case. Use AI to draft stronger claims that can withstand ANDA litigation.
Power Your Patent Strategy with PatSnap Eureka IP
From novelty searches to patent drafting, PatSnap Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical product development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation in the pharmaceutical space.
- View related patents in mirabegron technology space
- See which companies are active in similar drug formulation patents
- Understand ANDA litigation patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own generic drug or pharmaceutical product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
Multi-Patent Litigation Risk
Layered patent protection for MYRBETRIQ®
4 Patents Asserted
Covering formulation/method-of-use
Clear Outcome
Lupin admitted validity and infringement
✅ Key Takeaways
For Patent Attorneys & Litigators
Multi-patent ANDA enforcement strategies create compounding barriers to generic entry that are difficult to litigate around.
Search related case law →Consent judgments with explicit validity and infringement admissions provide durable, enforceable protections.
Explore precedents →Coordinating multiple civil actions in Delaware remains a preferred Hatch-Waxman enforcement architecture.
Explore Delaware Dockets →For IP Professionals
Patent portfolios covering a single drug product should span formulation, composition, and method-of-use claim types.
Start AI patent drafting →Patent term extension and regulatory exclusivity provisions must be explicitly incorporated into injunctive relief language.
Learn about regulatory exclusivities →For R&D Teams
Pre-ANDA FTO analyses must map all asserted patents and their extended expiration dates — not just base expiration.
Start FTO analysis for my product →Formulation design-around work should begin early in the development cycle, before regulatory filing.
Explore design-around strategies →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.